Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

The use of antibodies to target immune checkpoints, particularly PD-1/PD-L1, has made a profound impact in the field of cancer immunotherapy. Here, we identified KN035, an anti-PD-L1 nanobody that can strongly induce T-cell responses and inhibit tumor growth. The crystal structures of KN035 complexe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fei, Wei, Hudie, Wang, Xiaoxiao, Bai, Yu, Wang, Pilin, Wu, Jiawei, Jiang, Xiaoyong, Wang, Yugang, Cai, Haiyan, Xu, Ting, Zhou, Aiwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341541/
https://www.ncbi.nlm.nih.gov/pubmed/28280600
http://dx.doi.org/10.1038/celldisc.2017.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341541/
https://www.ncbi.nlm.nih.gov/pubmed/28280600
http://dx.doi.org/10.1038/celldisc.2017.4

Ejemplares similares